Select Page

Retinal Protection Sciences


Retinal Protection Sciences, LLC (RPS) is a medical research and development company focused on development of new and innovative technologies and process for addressing chronic progressive retinopathies (“CPRs”).


RPS was founded by Jeffrey K Luttrull, MD in 2016 to commercialize intellectual property (“IP”) developed under his leadership.  For nearly 20 years Dr. Luttrull has been responsible for of groundbreaking advancements in the use of retinal lasers for the restorative and therapeutic treatment of the most important CPRs.  These CPRs are the principle causes of irreversible visual loss today. Because of his innovative work in restorative retinal therapy, Dr. Luttrull is recognized as one of the world’s leading authorities on laser treatment of the retina. 


RPS is developing a class 2B medical device and system referred to as SAPRA™ (Safe-Pulse™ Retinal Activation™) system.  This laser system integrates the RPS IP and the unparalelled clinical laser experience of Dr. Luttrull into a “next generation” therapeutic laser that is specifically designed to avoid any damage to the eye while maximizing therapeutic effectiveness and efficiency. 


The SAPRA™ system is made up of proprietary confocal scanning laser ophthalmoscope video camera, split beam therapeutic laser, and proprietary automated safety technology. This automated safety technology includes groundbreaking Dynamic Dosimetry™ technology that measures retinal pigment density real-time to allow perfectly adjusted treatment parameters.  As a result, for the first time in the history of retinal laser treatment, the SAPRA system can safely avoid treatment concerns for patients with excessively high pigment density.


The SAPRA™ system will be first preventative and therapeutic treatment modality for the most important and widespread causes of irreversible blindness worldwide. These include age-related macular degeneration (AMD), diabetic retinopathy (DR), open angle glaucoma (OAG) and inherited retinal degenerations (IRDs) such as retinitis pigmentosa (RP). Each are forms of neurodegenerative disease, and as such, have much in common. The SAPRA™ is designed to address these commonalities to reverse the disease process, improve vision, and prevent visual loss.


RPS believes that the future of medical care will emphasize disease prevention and functional restoration through bioactivation; activation of the body’s own mechanisms for repair.  While we have powerful and highly effective systems for repair and regeneration, the key drivers of the chronic progressive diseases of ageing that plague the modern world do not  engage these processes.


The SAPRA™ system is designed to activate and engage these powerful natural restorative processes safely and effectively to slow, stop, or reverse disease progression, safely improve vision, and reduce the risks of vision loss. The SAPRA system uses patented processes in a highly automated format to deliver Retinal Protective Therapy™.  This therapy is optimized for maximum treatment safety, efficacy and comfort, and is administered in just seconds. We refer to this as SAPRA™ Laser Vision Protection.


 SAPRA™ can be thought of as the therapeutic analogue of Optical Coherence Tomography (“OCT”). The SAPRA™ system can be used to treat the things that OCT can be used to diagnose, and more. Thus, just as OCT revolutionized ophthalmic diagnosis, SAPRA™ will revolutionize ophthalmic therapy. The patient population that can benefit from the SAPRA™ system numbers nearly 1 billion persons worldwide. SAPRA™ is designed to meet that need – for therapy and prevention.  


RPS anticipates completion of the SAPRA™ system’s regulatory approval late in early 2020 and looks forward to providing those at risk for vision loss with this new, innovative and powerful tool.

Many of the SAPRA™ system’s innovative design, use and technologies are patent protected. Issued patents include:

·       U.S. Patent No. 9,381,115. System and process for retina phototherapy. Filed May 12, 2012; awarded July 5, 2016.

·       U.S. Patent No. 9,168,174. Process for restoring responsiveness to medication in tissues of living organisms. Filed January 25, 2015; awarded September 4, 2015

·       U.S. Patent No. 9,381,116. Subthreshold micropulse prophylactic treatment for chronic progressive retinal diseases. Filed October 23, 2015; awarded July 5, 2016.

·       U.S. Patent No. 9,427,602. Pulsating electromagnetic and ultrasound for stimulating targeted heat shock proteins for achieving retinal repair. Filed Oct 26, 2015; awared August 30, 2016.

·       U.S. Patent No. 9,962,291. System and process for neuroprotective therapy for glaucoma.  Filed: August 9, 2016, awarded May 1, 2018.

·       U.S. Patent No. 10,076,671. Apparatus for retinal phototherapy, filed July 1, 2016; awarded Sept 2018.

·       U.S. Patent No. 10,117,777. System for neuroprotective therapy for glaucoma. Filed Oct 24, 2916; awarded Nov 6, 2018.

·       U.S. Patent No. 10,219, 947. System and process for retina phototherapy. Filed March 13, 2013; awarded March 5, 2019.

·       U.S. Patent No. 10,238, 542. System and process for retinal phototherapy. Filed June 6, 2016; awarded March 26, 2019.

·       U.S. Patent No. 10,278,865. Process for neuroprotective therapy for glaucoma. Filed May 3, 2016; awarded May 7, 2019.

·       U.S. Patent No. 10,285,859. System for performing retinal photostimulation. Filed October 22, 2016. Issued May 14, 2019

·       U.S. Patent No. 10,299,961. System for neuroprotective therapy for glaucoma. Filed April 25, 2018. Issued May 28, 2019.

·         Appropriate protection has been sought for each of these US patents in other key jurisdictions throughout the world. Additionally, there are numerous applications pending that continue, expand and extend the core intellectual property of these patents.


 RPS Principals

Jeffrey K Luttrull, MD    Founder, Chief Executive and Medical Officer

Benjamin WL Margolis, MA   Chief Engineering Officer

David B Chang, PhD    Chief Scientific Officer

Harry Carneal    Chief of Business Development

Oculox Technologies SA  Strategic Engineering and Manufacturing Partner



  • This field is for validation purposes and should be left unchanged.